Using a commercially available time-resolved fluorescence resonance energy transfer (TR-FRET)-based assay for IKKβ, the authors have automated the assay procedure on a high-throughput screening station to carry out screening campaigns on multiwell plates. They have determined the Z′ factor and optimized volumes, times, and time-resolved fluorescence parameters. They have also compared 2 kinases with different fusion tags, the influence of different enzyme/substrate ratios and of DMSO presence at different concentration. The authors found that glutathione S-transferase (GST)-fused IKKβ shows better signal-to-noise (S/N) ratios over the poly-histidine-tagged variant. The substrate can be used at 50 nM with optimal performances when the enzyme is used at 2 nM. DMSO at 0.2% and 1% only slightly affects the S/N ratio, whereas when used at 2%, the final concentration deriving from a 50-fold dilution from a 5-mM stock solution in pure solvent, S/N undergoes a decrease of about 15%. Under the optimized conditions, the assay Z′ factor calculated over 192 data points has an optimized value of 0.881 and allows the testing of 94 molecules in quadruplicate in 140 min. (Journal of Biomolecular
INTRODUCTION

K
inases are ubiquitous enzymes that control a plethora of physiological and pathological functions. 1 They are generally activated by upstream kinases and work by transferring phosphate groups on other phosphate-containing mediators or on hydroxyl groups of amino acid side chains. Because of their high structure conservation, the finding of selective kinase inhibitors is a difficult task. 2, 3 In vitro screening of large arrays of compounds performed by automated screening stations is considered the strategy of choice [3] [4] [5] to identify effective compounds. In this field, automation and miniaturization of assays are essential requirements for the optimization of times and reagents that, in most cases, are very expensive or require complex processes for their preparation. 6 Although automation is needed to ensure reliability and rapidity of procedures, miniaturization and assay multiplexing are requested to minimize the amount of reagents needed to generate a single experimental data point. Most recent techniques for high-throughput screening (HTS) fulfill both requirements; indeed, accurate dispensing devices, sophisticated optical units, and high-density plate formats enable fast and reproducible delivery of tiny amounts of liquids, accurate determination of optical parameters, and the concurrent acquisition of thousand of data points. All these features must be paralleled by very sensitive techniques, such as time-resolved fluorescence resonance energy transfer (TR-FRET), [6] [7] [8] which couples the high sensitivity of time-resolved fluorescence with the high signal specificity deriving from selected FRET pairs. Among the most common FRET pairs, those using Europium complexes are the most sensitive and specific due to the long emission time (0.7-0.8 s), which allows large integration windows and therefore large lag times that help to cut off unwanted short-lived fluorescence signals. 9 TR-FRET has been usefully applied to kinase assays using Europium-labeled antibodies (anti-phosphopeptides), and commercial reagents are now available for testing selected inhibitors. 10 Eu 3+ -labeled antibodies (fluorescent donor) and peptide substrates derivatized with fluorescent acceptors (proteins such as allophycocyanin or synthetic dyes) are optimal combinations of FRET pairs that provide sufficient specificity and sensitivity for assays that make use of enzymes at nanomolar concentrations.
To transfer a TR-FRET assay for the kinase IKKβ on an automated station for HTS, we have first investigated parameters that can affect assay performances. Different enzyme preparations, reaction times, enzyme/substrate ratios, and the influence of different DMSO amounts have been studied, and the conditions for achieving optimal signal-to-noise (S/N) and Z′ factor values have been identified.
MATERIALS AND METHODS
Materials
The active His-tagged recombinant IKKβ was purchased from Upstate (Billerica, MA); the recombinant glutathione S-transferase (GST)-tagged active IKKβ was from Invitrogen (Milan, Italy).
The peptide of sequence RHDSGLDSM, corresponding to residues 29 to 37 of IKB-α, one of the multiple substrates of IKKβ, was used as a substrate. The peptide bears at its N-terminus a fluorofore commercially available as U-Light (PerkinElmer, Waltham, MA) that has maximum absorption at 615 nm and emission maximum at 665 nm. To detect substrate phosphorylation, we used a specific antibody anti-phospho-Ser32/ Ser36 of IKB-α (RHDpSGLDpSM). The antibody, purchased from PerkinElmer, was labeled with an Eu 3+ -cryptate fluorescent complex 10 with an absorption maximum at 340 nm and a timeresolved emission maximum at 615 nm. For detection, a commercially available buffer named LANCE Detection Buffer was used (10×, PerkinElmer). White plates (OPTI PLATE) with 384 wells at reduced volume (total volume 30 µL) from PerkinElmer were used throughout the experiments. HEPES buffer, adenosine triphosphate (ATP), and EDTA were from Sigma-Aldrich (St. Louis, MO). The assay was automatized on a fully equipped Hamilton station Starlet 8, comprising an 8-channel liquid handler with electronic control of volumes on each single channel and conductive disposable tips, a gripper for object moving, and a robotic arm to transfer plates outside the liquid handler platform. A BioTek Synergy 2 fluorescence reader, supplied with proper filters (ex: 320/40 nm; em: 615/10 nm; em: 665/7 nm), was employed to read wells.
Methods
For assays on full 384-well plates, the IKKβ kinase solution (2.2 mL) was prepared at a 2× concentration (4 nM) in Kinase Buffer (KB, 50 mM HEPES, 50 mM dithiothreitol, 10 mM MgCl 2 ). The U-Light-IKB-α peptide/ATP mix solution was prepared by diluting the U-Light-IKB-α peptide up to a concentration of 200 nM in KB containing ATP at 80 µM (2.0 mL total volume). Solutions of inhibitors (200 µL) were prepared in 96-well plates (source plate) at a 4× concentration in kinase buffer. The detection buffer was prepared from the stock 10× LANCE buffer solution by dilution in deionized water. The detection solution containing the Eu 3+ -conjugated antibody was combined with the Stop solution (EDTA) and added in 1 single step. For this purpose, the solution (2.2 mL) was prepared by mixing 1.0 mL of a 4× Stop solution, containing EDTA 40 mM in 1× LANCE Detection Buffer and 1.0 mL of a 4× solution of Eu 3+ -labeled antibody anti-phospho-IKB 8 nM in 1× LANCE Detection Buffer. Phosphorylation of the substrate was monitored by TR-FRET by exciting at 340 nm and reading the emitted fluorescence at 665 nm (see Fig. 1 ). FRET occurs only when the substrate is phosphorylated. Measurement parameters are reported in the supplemental Table S1 (see http://jbx.sagepub. com/supplemental). The Z′ factor was calculated as reported in Zhang et al. 11 Data were manipulated and plotted using the software GraphPad Prism 4, Version 4.02 (GraphPad, Inc., San Diego, CA). Normalization was achieved by dividing the fluorescence value at 665 nm by the fluorescence value at 615 nm in the same well to take into account differences in dispensing the antibody solution. The protocol was developed using the software implemented for the Hamilton station and following -labeled antibody anti-phospho-Iκb and the commercial dye known as U-Light. Following excitation at 340 nm, a specific fluorescence signal is detected at 665 nm only when the substrate is phosphorylated on the 2 serines by the specific IKKβ kinase. The emission at 615 nm due to the Eu 3+ complex is also detected during the assay and used to normalize with respect to the added antibody. 
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The main steps of the procedure are outlined below:
• Dispense 2.5 µL of KB or inhibitor solution into a 384-well white OptiPlate-384.
• Add 2.5 µL of U-Light-IκB-α peptide/ATP mix solution (2 nM and 2 µM final concentration, respectively).
• Add 5 µL of IKKβ enzyme (2-10 nM final concentration).
• Cover plate and incubate for 1 h at room temperature (RT).
• Stop kinase reactions by adding 10 µL of Stop/Detection mix.
• Cover with Top-Seal-A and incubate for 1 h at RT.
• Remove TopSeal-A and read signal with the BioTek Synergy 2 in TR-FRET mode using the excitation filter at 320/40 nm and the emission filters at 665/7 nm for the U-Light and at 620/10 nm for determining the Europium emission.
RESULTS AND DISCUSSION
Conditions for the automated execution of TR-FRET-based screening assays of IKβ kinase inhibitors have been optimized.
We have used commercially available reagents and an integrated HTS station to set up the protocol and to investigate enzyme source and type, enzyme concentration, and time of reaction. We have next investigated the influence of DMSO concentration on S/N as most compounds are stored as stock solutions in neat DMSO at high concentrations (>5 mM).
Two enzyme variants, differently tagged with GST (GST-IKKβ) and with polyhistidine (His 6 -IKKβ), have been used. The U-Light-derivatized substrate has been chosen and used at a fixed 50-nM concentration. 10 The HTS assay protocol finally has been designed on the basis of the selected assay conditions. To reduce costs and times, we used 384-well white plates with reduced volume.
At first, a study on the dependence of S/N from reaction time, enzyme concentration, and enzyme type was performed. Two IKKβ variants were purchased from 2 different companies, aliquoted, and stored at -80 °C under the same conditions. The 2 enzymes were tested just upon arrival and after 1 month of storage at -80 °C to monitor possible loss of activity. In Figure 2 , comparative plots of data obtained for the 2 enzymes upon arrival are reported. Each data point was determined by averaging quadruplicates. Enzymes were tested at 0, 1, 2, 5, and 10 nM and monitored over time between 0 and 60 min. Without enzyme, a constant value of normalized FRET of about 0.15 was observed at all times. Instead, as shown in Figure 2A , at the different concentrations, the 2 variants exhibited different performances; indeed, the GST-fused protein showed an acceptable and significant signal even at 1 nM, with values of normalized FRET of about 1.5 (S/N ≈ 10) after 60 min ( Fig. 2A) . At 2 nM, a value of normalized FRET of about 3.0 (S/N ≈ 20) was reached after 30 min, whereas at 5 and 10 nM, the signal was saturated after only 15 min with FRET values of 4.5 (S/N ≈ 30). Conversely, with the poly-histidine-tagged enzyme used at 1 nM, values not significantly different from those obtained without enzyme were recorded (Fig. 2B) . A signal similar to that recorded with the GST-tagged IKKβ at 2 nM was instead obtained only with a concentration of His 6 -IKKβ of 5 nM (1.5-fold higher). When the 2 enzymes were tested after 1 month of storage at -80 °C, values were all reduced at about 40% (Fig.  2C,D) , although the relative tendency observed with the fresh enzymes was preserved under these conditions. GST-IKKβ was indeed more active than His 6 -IKKβ, displaying values of normalized FRET of about 2.0 (S/N ≈ 13) at 2 nM after a 60-min reaction time. Altogether, data show that the GST-tagged enzyme features better performances in terms of S/N and speed to reach plateau values (15 min at 5 nM vs. 30 min at 10 nM for the His 6 -fused variant) and that both proteins stored frozen for 1 month undergo a 40% activity reduction, likely due to degradation or autophosphorylation events occurring also at very low temperatures. On the basis of these results, we decided to use the GST-fused enzyme at 2 nM, leaving the reaction to proceed for 60 min in the dark at 25 °C. We next proceeded to automate the assays using the fluorescent substrate at 50 nM and the Europium-labeled anti-phospho-Iκb antibody at 2 nM, as also indicated by the manufacturer. The reaction total volume was 20 µL. The full protocol is described in detail in the Methods section, whereas the measurement parameters are reported in Table S1 in the supplemental material (see http://jbx.sagepub. com/supplemental). The protocol has a duration of 140 min and includes the following main steps: (1) delivery of 2.5 µL of buffer or inhibitor solution, (2) delivery of 2.5 µL of 200 nM enzyme substrate, (3) delivery of 5.0 µL of 4 nM enzyme solution, and (4) delivery of 10 µL of 4 nM antibody solution containing 40 mM EDTA to stop the kinase reaction.
In the first step, proper delivery of inhibitor solution in the empty wells is performed by setting the value at 3.0 µL and allowing tips to touch the well bottom. This value was experimentally determined after several trials, exploiting the substrate fluorescence and using a reference curve (not shown) to monitor liquid delivery. The slight increase of volume was not needed for the second step of liquid addition (compounds), as dispensing was performed by sensing the liquid level and exploiting the electrostatic liquid attraction. Using 2.5 µL of compound solution on a total reaction volume of 10 µL (before addition of the antibody plus the stop solution) implies a 4-fold higher concentration of compound solutions. Because all compounds are dissolved at 5 mM in DMSO and we expect to screen them at the maximum final concentration of 100 µM, a predilution step up to 400 µM is needed. Dilution is performed in KB, and therefore a final 2% DMSO is present in the final reaction mixture. The highest possible volume of enzyme solution (5 µL) is added at this step to minimize errors of dispensing of the precious material. After a 60-min reaction time, the antibody is added at 2-fold the final concentration (4 nM); addition of EDTA in the same buffer stops the reaction by subtracting the Mg 2+ ions required for phosphate transfer. Again, the volume of the added antibody solution is fixed at the highest possible value to reduce pipetting errors of this expensive reagent.
Importantly, the protocol was designed to easily transfer 4 aliquots of the same material from a "mother" 96-well polypropylene plate into the corresponding 384-well, low-volume plate (see Fig. S1 in supplemental material at http://jbx.sagepub. com/supplemental). Following this protocol and introducing a positive (no inhibitors) and a negative control (no ATP addition), 94 compounds can be screened in parallel in quadruplicate. After fixing all parameters for optimal dispensing and plate reading (reported in Table S1 at http://jbx.sagepub.com/ supplemental), we determined the Z′ factor for the assay. To this aim, a full 384-well plate was processed using the screening station. In 192 wells (half plate), we replicated the assay without inhibitors (positive controls), whereas in the second half plate, the same reaction without ATP (negative controls) was performed. The enzyme was used at 2 nM, the substrate was used at 50 nM, and the antibody was used at a final concentration of 2 nM. The plot reported in Figure 3A shows that an average value of 3.0 of normalized FRET was obtained and that data were highly reproducible. Consequently, the calculated Z′ factor for this experiment was 0.881, with µ p , σ p , µ n , and σ n being 2.981, 0.1088, 0.06607, and 0.007001, respectively (1). Data obtained in this assay were also consistent with those reported in Figure 2A , where the same normalized FRET value was observed under these conditions. The average S/N determined in this assay (≈30) was somehow greater than that previously calculated (≈20), but in this case, the noise value was referred to the "no-ATP" conditions instead of the "noenzyme" condition, as in the previous experiment.
We next evaluated the effects of DMSO presence on the S/N values and on the Z′ factor. Although time-resolved fluorescence should not in principle be affected by solvents, the presence of such solvents and their eventual contaminants cannot be neglected.
To this purpose, we performed a new assay in the presence of 0.2%, 1%, and 2% DMSO. Solvent percentages were chosen on the basis of the concentration of compound stock solutions in pure DMSO (5 mM); therefore, 0.2% DMSO corresponds to compound concentrations of 10 µM, 1% DMSO corresponds to compound concentrations of 50 µM, and 2% DMSO corresponds to compound concentration of 100 µM. In Figure 3 , bar plots relative to the results obtained are reported. As shown, DMSO at 0.2% and 1% had no apparent effects on the absolute normalized FRET values, which were all very similar to those obtained without solvent (Fig. 3B,C) . Also, the standard deviation (SD), as calculated from quadruplicate data deriving from the same source well (see Fig. S1 at http://jbx.sagepub.com/supplemental), was very low, with SD values being below 5% of the arithmetic mean of experimental data. When the solvent was added at 2%, a relevant reduction of the overall signal was observed (about 15%; Fig. 3D ). In addition, this last assay featured an average S/N of 19 compared to about 28 for the 0.2% and about 25 for the 1% solvent addition. The respective Z′ factors were 0.8245 at 0.2%, 0.7590 at 1%, and 0.6264 at 2% (calculated over the 28 data points for each distinct DMSO concentration).
We finally tested our automated procedure in a dose-dependent assay using the known IKKβ inhibitor 2-[(aminocarbonyl) 12 which has a reported IC 50 of 17.9 nM. TPCA-1 was tested at concentrations between 1250 nM and 0.038 nM (15 points in quadruplicates). In Figure 4 , the inhibition curve obtained by nonlinear data fitting is reported, from which an IC 50 of 26.9 ± 1.0 nM was measured. This value, obtained over several assays under the same conditions, is very close to that reported in the literature, and therefore the automated method appears reliable also for dose-dependent assays, as the low discrepancy observed could likely be ascribed to the presence of water within the dry sample.
In conclusion, we have automated a TR-FRET-based screening assay for findings inhibitors of IKKβ. The method is very reproducible and robust with an optimized Z′ factor calculated over more than 190 data points of 0.881. When applied to 384-well plates with a 20-µL reaction volume, the time for assaying 94 different compounds in quadruplicate is 140 min. A kinase variant having GST at its N-terminus has shown better performances in terms of S/N ratios compared to the His 6 -tagged variant. Data also show that this enzyme, when used at 5 nM, could allow a reaction time of only 15 min, thus reducing the total assay time to 95 min. The presence of small amounts of DMSO does not affect the assay performances when used up to 1%, whereas a 15% decrease of the average S/N values is observed when the solvent concentration reaches 2%. The automated procedure used for a dose-dependent assay provides IC 50 values for a known IKKβ inhibitor very close to that previously reported, confirming the ruggedness and reliability of the automated method. -1) . The compound has a reported IC 50 of 17.9 nM. The value determined under our conditions and using the automated station was 26.9 ± 1.0 nM. 
